| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| CAGR | 4.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Tourette Syndrome Treatment Market Analysis
The Tourette Syndrome Treatment Market is expected to register a CAGR of 4.5% during the forecast period.
The major factors driving the market's growth are the increasing cases of Tourette syndrome across the world and the rising focus on Tourette syndrome research.
The increasing research work and studies on Tourette syndrome (TS) to investigate underlying causes and treatment efficacy across the globe are also anticipated to propel market growth. For instance, according to the data released by ClinicalTrials.gov as of July 2024, Tourette syndrome (TS) and chronic tic disorder (CTD) affect approximately 222 studies reported on the clinical trials.gov websites. Thus, this high number of studies on such rare diseases is expected to contribute to the segment's growth during the forecast period.
Further, the growing burden of Tourette syndrome is expected to increase demand for the treatment, which is likely to bolster the segment's growth during the forecast period. For instance, according to the article published in F1000 Research in October 2023, annual incidence rates of Tourette syndrome (TS) have been on the rise in childhood. In China, the prevalence of TS disorders among school students aged 6 to 16 stands at 1.37% annually. Thus, the high prevalence of TS is anticipated to boost the demand for its treatment, thereby boosting the market's growth during the forecast period.
Moreover, the rising funding activities for the research and development of Tourette syndrome drug treatment are anticipated to boost segment growth over the forecast period. For instance, in November 2022, Emalex Biosciences closed a Series D funding of around USD 250 million for its phase III trial of ecopipam drug for Tourette syndrome.
Further, ongoing research on the development treatment for Tourette syndrome is expected to contribute to the segment growth over the forecast period. For instance, in February 2024, Baylor Medicine unveiled a comprehensive study spanning multiple centers. This double-blind, placebo-controlled, randomized withdrawal study aims to assess the safety and efficacy maintenance of ecopipam in individuals across various age groups, children, adolescents, and adults suffering from Tourette's disorder. The primary objective is to ascertain whether ecopipam, an experimental drug, outperforms no medication in managing Tourette's Disorder and its associated tics.
Therefore, the high prevalence of TS across the world and the rising number of clinical trials are projected to drive market growth during the forecast period. However, a lack of awareness about Tourette syndrome in developing regions is likely to impede the market's growth over the forecast period.
Tourette Syndrome Treatment Market Trends
The Antipsychotics Segment is Expected to Witness Significant Growth During the Forecast Period
Antipsychotic drugs are expected to hold a significant market share due to their ability to treat tics to a greater extent than non-antipsychotic drugs. Antipsychotic drugs were developed for treating schizophrenia, hence the term antipsychotic. These medications work by blocking another chemical in the brain called dopamine, specifically by blocking dopamine receptors, mainly the D2 receptor. Thus, such a robust therapeutic effect of antipsychotics is one of the significant factors driving the segment's growth during the forecast period.
The increasing use of antipsychotic drugs and their efficacy in treating Tourette syndrome is one of the major factors driving the segment's growth during the forecast period. For instance, as per the study published by Cureus Journal in February 2022, antipsychotic drugs have been commonly used as a treatment for Tourette syndrome since Food and Drug Administration approval. Haloperidol and pimozide have been used for a long time and have shown significant efficacy. Haloperidol can cause a 91.0% reduction in the severity of tics when given at the maximum dose. Therefore, such instances indicating the high effectiveness of antipsychotic drugs in treating the Tourette syndrome segment are projected to drive the segment's growth during the forecast period.
Furthermore, the rising number of clinical trials testing the efficacy of antipsychotic drugs for treating TS disease is also projected to drive segment growth during the forecast period. For instance, in March 2023, Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for treating Tourette Syndrome.
Therefore, the high efficacy of antipsychotic drugs in treating TS and the rising number of clinical trials are projected to drive the segment's growth during the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold a Significant Market Share During the Forecast Period
North America is expected to register a significant share in the Tourette syndrome treatment market owing to the increasing prevalence of Tourette syndrome, growing awareness, and strategic initiatives taken by the market players, such as research and clinical development.
The growth is due to factors such as the increasing prevalence of Tourette syndrome and increasing research related to the syndrome in this region. For instance, as per the report published by Tourette Canada in January 2022, Tourette syndrome affects approximately 1.0% of the population. However, some recent studies suggest that the prevalence rate may be as high as 3.8%. Tics are quite common in childhood, with studies showing that 24.0% of children may develop simple tics. Therefore, such instances indicate that the demand for Tourette syndrome treatment may increase, propelling the market's growth for treatments.
Furthermore, several regional awareness campaigns to educate people on diseases and treatment plans are anticipated to boost the market's growth during the forecast period. For instance, the Tourette Association of America celebrates Tourette Syndrome Awareness Month from May 15 to June 15 every year to increase awareness about the syndrome among people. Thus, such instances are anticipated to drive the market's growth in the country.
Key product launches, high concentration of market players or manufacturer's presence, acquisitions and partnerships among major players, and public and private initiatives toward Tourette syndrome in the United States are some of the factors driving the growth of the Tourette syndrome treatment market in the country. For instance, in April 2023, Camber Pharmaceuticals expanded its product line by introducing Aripiprazole Oral Solution, enhancing its existing range that already features Aripiprazole Tablets, primarily utilized in treating Tourette's disorder.
Therefore, owing to the aforementioned factors, the market's growth is anticipated to grow in North America.
Get Analysis on Important Geographic Markets
Download PDF
Tourette Syndrome Treatment Industry Overview
The Tourette syndrome treatment market is consolidated, with most players competing to increase their market share. Rising competition, rapid technological advancements, and a focus on research are key factors that strongly impact the market. The competitive landscape includes an analysis of a few international and local companies that hold the market shares and are well known, including AstraZeneca PLC, Viatris Inc. (Mylan Inc.), Otsuka Holdings Co. Ltd, Reviva Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd (Auspex Pharmaceuticals Inc.).
Tourette Syndrome Treatment Market Leaders
-
AstraZeneca Plc
-
Viatris Inc. (Mylan Inc.)
-
Otsuka Pharmaceutical Co., Ltd.
-
Reviva Pharmaceuticals Inc.
-
Teva Pharmaceutical Industries Ltd. (Auspex Pharmaceuticals, Inc.)
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Tourette Syndrome Treatment Market News
- September 2023: SciSparc launched a Phase IIb clinical trial for its SCI-110 drug, targeting Tourette Syndrome (TS), a neurodevelopmental disorder. This trial, which is randomized and double-masked, is commencing at the Tel Aviv Sourasky Medical Center in Israel.
- October 2023: Emalex Biosciences disclosed the outcomes of a 12-month open-label extension study on its Tourette Syndrome treatment candidate. The study, involving 121 pediatric patients diagnosed with Tourette syndrome, focused on assessing the safety of the experimental drug ecopipam over a 12-month treatment period.
Tourette Syndrome Treatment Industry Segmentation
As per the scope of the report, Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Tourette syndrome is associated with other additional neurobehavioral problems such as inattention, impulsivity (attention deficit hyperactivity disorder-ADHD), problems with reading and writing, and obsessive-compulsive symptoms.
The Tourette syndrome treatment market is segmented by product and geography. By product, the market is segmented as antipsychotics and non-antipsychotics. By geography, the market is segmented as North America, Europe, Asia-Pacific, and the rest of the world. The report offers the value (USD) for the above segments.
| By Product | Antipsychotics | ||
| Non-antipsychotics | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Rest of the World | |||
Need A Different Region or Segment?
Customize Now
Tourette Syndrome Treatment Market Research FAQs
What is the current Tourette Syndrome Treatment Market size?
The Tourette Syndrome Treatment Market is projected to register a CAGR of 4.5% during the forecast period (2025-2030)
Who are the key players in Tourette Syndrome Treatment Market?
AstraZeneca Plc, Viatris Inc. (Mylan Inc.), Otsuka Pharmaceutical Co., Ltd., Reviva Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. (Auspex Pharmaceuticals, Inc.) are the major companies operating in the Tourette Syndrome Treatment Market.
Which is the fastest growing region in Tourette Syndrome Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Tourette Syndrome Treatment Market?
In 2025, the North America accounts for the largest market share in Tourette Syndrome Treatment Market.
What years does this Tourette Syndrome Treatment Market cover?
The report covers the Tourette Syndrome Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Tourette Syndrome Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
TIC Disorder Industry Report
Statistics for the 2025 Tourette Syndrome Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Tourette Syndrome Treatment analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
